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BACKGROUND: The presence of Gleason pattern 5 (GP5) at radical prostatectomy (RP) has been associated with worse clinical out-
come; however, this pathologic variable has not been assessed in patients receiving salvage radiation therapy (SRT) after a rising
prostate-specific antigen level. METHODS: A total of 575 patients who underwent primary RP for localized prostate cancer and sub-
sequently received SRT at a tertiary medical institution were reviewed retrospectively. Primary outcomes of interest were biochemical
failure (BF), distant metastasis (DM), and prostate cancer-specific mortality (PCSM), which were assessed via univariate analysis and
Fine and Grays competing risks multivariate models. RESULTS: On pathologic evaluation, 563 (98%) patients had a documented Glea-
son score (GS). The median follow-up post-SRT was 56.7 months. A total of 60 (10.7%) patients had primary, secondary, or tertiary
GP5. On univariate analysis, the presence of GP5 was prognostic for BF (hazard ratio [HR] 3.3; P< .0001), DM (HR:11.1, P< .0001), and
PCSM (HR:8.8, P<.0001). Restratification of the Gleason score to include GP5 as a distinct entity resulted in improved prognostic
capability. Patients with GP5 had clinically worse outcomes than patients with GS8(414). On multivariate analysis, the presence of
GP5 was the most adverse pathologic predictor of BF (HR 2.9; P< .0001), DM (HR 14.8; P< .0001), and PCSM (HR 5.7; P<.0001).
CONCLUSION: In the setting of SRT for prostate cancer, the presence of GP5 is a critical pathologic predictor of BF, DM, and PCSM.
Traditional GS risk stratification fails to fully utilize the prognostic capabilities of individual Gleason patterns among men receiving
SRT post-RP. Cancer 2013;119:3287-94. VC 2013 American Cancer Society.
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INTRODUCTION
Approximately 30% of patients undergoing radical prostatectomy (RP) for localized prostate cancer will experience bio-
chemical recurrence.1,2 Salvage external beam radiation therapy (SRT) is known to improve various measurements of out-
come, including biochemical failure (BF), distant metastasis (DM), and likely prostate cancer-specific mortality (PCSM)
for those with a rising prostate-specific antigen (PSA) post-RP.3-6
The overall response rate to SRT following RP leaves room for improvement, with long-term progression-free sur-
vival estimated at less than 50%.5,7 However, some patients obtain long-term control while others may benefit from earlier
or more intensive therapy. Prognostic factors following SRT include pre-SRT PSA, use of androgen deprivation therapy
(ADT), overall Gleason score (GS), extracapsular extension, surgical margins, seminal vesicle invasion, PSA doubling
time (PSADT), and lymph node invasion.4,7
The presence of Gleason pattern 5 (GP5) is associated with increased recurrence and metastasis following primary
treatment of localized prostate cancer with EBRT, RP, or brachytherapy.8-14 However, it is unclear what role the presence
of GP5 has for patients considering SRT after biochemical recurrence post-RP. Because GP5 may be a predictor of both
local and=or distant failure, analysis of its prognostic significance for those treated with SRT is a significant unmet clinical
need. SRT is commonly used following biochemical recurrence after RP, and the presence or absence of GP5 could
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significantly influence treatment recommendations, such
as the use of pelvic RT15 and the potential use of ADT16
or other salvage therapies.
MATERIALS AND METHODS
Patient Selection
Through an institutional review board-approved retro-
spective analysis, 575 patients were identified who under-
went primary RP for localized prostate cancer and
subsequently received SRT with or without ADT between
1986 and 2010. Patients receiving SRT were identified as
those receiving radiation therapy for an elevated post-RP
PSA level 0.2 ng/mL.17 Ten patients had a detectable
PSA level following RP and were started on ADT prior to
SRT, which resulted in an undetectable pre-SRT PSA
level (represented as a pre-SRT PSA level of 0 ng=mL).
Pathologic GS was available for 563 (98%) patients, who
comprised the cohort for this analysis.
Treatment
SRT was delivered using 3-dimensional conformal or
intensity-modulated radiation therapy. The range of pre-
scribed radiation doses was 59.1-76.2 Gy, with >95% of
patients receiving 64.8-70.2 Gy. Whole-pelvic radiation
therapy was used in 15.9% of patients and was usually
prescribed to high-risk patients. ADT during SRT was
prescribed at the treating physician’s discretion based on
patient risk factors.
End Points
Outcomes measured included BF, DM, and PCSM.
Time to BF, DM, and PCSM were calculated from the
SRT start date. BF was defined as a serum PSA level at
least 0.2 ng=mL greater than the post-SRT nadir followed
by a second higher serum PSA level,7 or any single level
greater than 0.5 ng=mL above the post-SRT nadir. DM
was defined as the presence of clinical, radiologic, or path-
ologic evidence of metastasis. PCSM was defined as any
death in a patient with prostatic metastasis, hormone re-
fractory disease, or death attributed to prostate cancer.
Statistical Analysis
The chi-square test and one-way analysis of variance were
used to compare categorical and continuous variables,
respectively. Survival and multivariate analysis were per-
formed using the log-rank test and Kaplan-Meier meth-
ods and Fine and Grays competing risks methods,18
respectively. All statistical analyses were performed using
MedCalc (version 12.3.0.0; MedCalc Software, Maria-
kerke, Belgium) and Stata (version 12.1; StataCorp LP,
College Station, Tex.).
RESULTS
Patient Characteristics
Patients had a median age of 65.2 years (interquartile
range [IQR] 59.7-70.0), a median age-unadjusted Charl-
son comorbidity index of 0.0 (IQR 0-1),19 and a median
follow-up of 56.7 months following SRT. The median
time between surgery and SRT was 30 months (IQR 13-
57). Patients with GP5 on average had a sorter interval
between surgery and SRT than patients without GP5
(25.3 months vs 40.7 months, respectively; P5 .001).
The median total SRT dose was 68.4 Gy, which was not
different in patients with or without GP5 (P5 .1).
Androgen deprivation therapy concurrent with SRT was
used in 20% of all patients for a median duration of 11
months (IQR 6-24), and although patients with Gleason
8-10 disease were more likely to receive adjuvant ADT,
there was no difference in either duration of ADT or in
the use of ADT in patients with Gleason 8-10 with or
without GP5.
Pretreatment, pathologic, and treatment-related
patient characteristics as stratified by adjusted GS,
accounting for the presence or absence of GP5, are shown
in Table 1. Patients were stratified into 4 groups: 1) those
with GS2-6, 2) those with GS7, 3) those with GS8 with-
out GP5 (Gleason 414), and 4) those with primary, sec-
ondary, or tertiary GP5, henceforth referred to as the GP5
group. Four of the GP5 patients had primary GP5, 32
had secondary GP5, 10 had tertiary GP5, and 14 had a
description of GP5 disease without notation of whether
this represented the primary versus the secondary pattern.
No patient had GS10(515). Of the patients with tertiary
GP5, 1 was GS7(314), 6 were GS7(413), and 3 were
GS8(414). There was no difference in duration of
follow-up post-SRT by GS groupings (P5 .6).
Univariate Analysis
On univariate analysis, the traditional risk stratification of
Gleason sum (2-6, 7, 8-10) significantly predicted BF
(P5 .001) and DM (P5 .001), with a trend toward pre-
dicting PCSM. Restratification of the GS with GP5 as the
high-risk group significantly predicted BF, DM, and
PCSM (all P< .0001). This stratification is demonstrated
via Kaplan-Meier analysis in Figure 1.
There was a trend toward increased BF for those
with GP5 as compared to those with GS8(414) (HR:1.5,
P5 .07). However, the presence of GP5 predicted for
increased DM (hazard ratio [HR]:2.2, P5 .02) and
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PCSM (HR:2.6, P5 .03) when compared with patients
with GS8(414). No difference was observed in BF, DM,
or PCSMwhen comparing patients with primary, second-
ary, tertiary, and unknown GP5s on univariate analysis.
The 5-year rates of BF, DM, and PCSM for patients with
GP5 compared with patients with GS8(414) were 74%
versus 67%, respectively, for BF; 44.9% versus 17.5%,
respectively, for DM; and 17.7% versus 4.7%, respec-
tively, for PCSM. Although 5-year rates of BF were not
statistically different for patients with GP5 compared
with those with GS8(414), patients with GP5 were more
likely to experience an early BF than GS8(414) patients.
The median time to BF was 15.2 months (IQR 8.6-33.4)
for patients with GP5 and 21.8 months (IQR 13.3-48.6)
for patients with GS8(414). Fifty-six percent of patients
with GP5 experienced BF within 18 months of SRT com-
pared with 37% of patients with GS8(414).
Other variables associated with BF, DM, and PCSM
on univariate analysis included pre-radiation therapy PSA
level, PSADT, seminal vesicle invasion, surgical margins,
and extracapsular extension (Table 2).
Multivariate Analysis
Competing risks multivariate analysis was performed
using significant variables from univariate analysis. The
use of concurrent ADT with SRT and whole-pelvic RT
were included in the multivariate analysis to control for
intensification of treatment that may have occurred for
patients with GP5. The start date of SRT was likewise
included to control for time-related biases in treatment
and Gleason scoring. Patients receiving ADT for a persis-
tently elevated PSA post-RP (n5 10) were excluded from
multivariate analysis to prevent biases that may have arisen
with their inclusion. PSADT was not included in the ini-
tial model, as sufficient data to calculate this variable was
only available for 49% of the cohort. However, no statisti-
cally significant difference existed between those patients
with and without a determinable PSADT for any of our
three primary outcomes (BF, DM, PCSM, all P> .1 by
log-rank). Thus, multivariate analysis was first performed
by including all variables of interest and excluding
PSADT (Table 3) and was next performed using a step-
wise competing risks multivariate model, to limit overfit-
ting of the model that included all variables (Table 4).
Recognizing the importance of PSADT, a final stepwise
model was created that also included pre-SRT PSADT
(Table 5). Although the hazard ratios associated with the
presence of GP5 were smaller in the model including
PSADT, the hazard ratios for DM and PCSM were iden-
tical if the model was rerun including only the subset of
TABLE 1. Pretreatment, Pathologic, and Treatment-Related Patient Characteristics Stratified by Gleason
Score and GP5
Characteristics
Gleason Score P
2-6 (n 5 140) 7 (n 5 295) 8(414) (n 5 68) GP5 (n 5 60) Overall
GP5 vs
8(414)
Age, y, median (IQR) 66.1 (60.9-70.2) 64.2 (59.4-69.8) 67.6 (61.8-70.8) 62.8 (57.8-67.3) .02a .6a
CCMI, median (IQR); range 0.0 (0.0-1.0); 0-4.0 0.0 (0.0-0.0); 0-4.0 0.0 (0.0-1.0); 0-2.0 0.0 (0.0-1.0); 0-2.0 .6a .9a
Pre-SRT PSA, ng/mL,
median (IQR); range
0.6 (0.4-1.4); 0-27.1 0.6 (0.4-1.1); 0-11.8 1.1 (0.4-2.3); 0.1-13.6 0.7 (0.3-1.5); 0.1-17.4 .01a .4a
Pre-SRT PSADT, mo,
median (IQR); range
11.8 (7.0-21.5); 0.6-42.1 7.8 (4.3-15.3); 0.8-121.5 6.4 (3.2-13.9); 0.8-23.9 5.8 (4.4-13.6); 0.6-117.9 .2a .4a
PSA nadir post-SRT,
median (IQR); range
0 (0-0.1); 0-9.4 0 (0-0.3); 0-33.4 0 (0-0.2); 0-20.1 0 (0-0.2); 0-6.3 .4a .6a
SRT dose, Gy, median (IQR) 68.4 (64.8-68.4) 68.4 (64.8-68.4) 68.4 (59.1-70.8) 68.4 (64.8-68.4) .2a .1a
Pelvic RT, % 14.4 13.3 26.9 20.0 .04b .5b
ADT during SRT, % 20.7 15.9 26.5 33.3 .01b .5b
ADT duration, mo, median (range) 8.0 (5.9-14.3) 12.3 (6.0-23.9) 10.7 (5.9-23.8) 9.2 (5.5-23.8) .5a .7a
Pathologic T stage, % .03b .04b
T1-T2a 14.0 9.3 7.0 0
T2b-T2c 24.7 25.1 22.8 13.0
T3-T4 61.3 65.6 70.2 87.0
Seminal vesicle invasion, % 6.6 13.4 25.0 45.0 <.0001b .03b
Positive margins, % 51.9 50.0 43.7 60.0 .3b .09b
Extracapsular extension, % 42.1 55.6 58.8 74.6 .0004b .09b
Lymph node involvement, % 4.3 1.2 7.4 9.1 .049b .8b
Abbreviations: ADT, androgen deprivation therapy; CCMI, Charlson comorbidity index; GP5, Gleason pattern 5; IQR, interquartile range; PSA, prostate-specific
antigen; PSADT, prostate-specific antigen doubling time; RT, radiation therapy; SRT, salvage radiation therapy.
a Analysis of variance.
bChi-square.
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patients with PSADT available, but excluding PSADT as
a variable in the model. This finding suggests that the
smaller hazard ratios associated with GP5 in the PSADT
model are a result of the smaller sample size, and not a
result of the influence of PSADT.
In all models, the presence of GP5 was the most
adverse pathologic predictor of BF, DM, and PCSM.
Lastly, to evaluate the volume of GP5 present, an explora-
tory analysis was performed using a stepwise competing
risks multivariate model in which the presence of GP5
was separated into 2 variables: those with primary GP5,
and those with secondary or tertiary GP5. Both primary
and secondary=tertiary GP5 werez significantly associated
with all outcomes; however, the presence of primary
GP5 was associated with a greater hazard than
secondary=tertiary=unknown GP5 for BF (HR 4.0, 95%
confidence interval [CI] 1.2-12.9, P5 .02 vs HR 2.9,
95% CI 1.7-4.8, P< .0001, respectively), DM (HR 22.2,
95% CI 4.0-122.6, P< .0001 vs HR 14.5, 95% CI 4.0-
52.1, P< .0001, respectively), and PCSM (HR 10.6,
95% CI 2.4-47.4, P5 .002 vs HR 5.2, 95% CI 2.0-13.8,
P5 .001, respectively). Given that only 4 patients had
primary GP5, additional analyses distinguishing between
primary and secondary=tertiary GP5 were not performed.
Salvage Androgen Deprivation Therapy
Although the presence of GP5 was the most adverse path-
ologic predictor of poor patient outcomes on univariate
and multivariate analysis, an analysis was performed to
ensure that the worse outcomes were not secondary to dif-
ferences in the use of salvage ADT (sADT). The time to
first use of sADT following BF (Fig. 2A) and the time
from the initiation of sADT to DM (Fig. 2B) were
assessed for patients with and without GP5. Patients with
GP5 were more likely to receive sADT earlier and more
often following BF (HR 1.8, P5 .01) than those without
GP5. Likewise, patients with GP5 developed metastasis at
a faster rate following the use of first sADT (HR 2.2,
P5 .01) than patients without GP5.
DISCUSSION
The Gleason score is one of the most critical risk-factors
for prostate cancer patients treated with SRT.4,5,7 Tradi-
tional risk stratification by GS groups GS2-6, GS7, and
GS8-10 has been shown to be an important prognostica-
tor of outcomes for those receiving SRT post-RP.7 While
this stratification of GS is prognostic of various outcomes
for SRT, it fails to take full advantage of the individual
Gleason patterns that comprise the GS. Nanda et al. dem-
onstrated that in patients undergoing primary up-front
Figure 1. Freedom from biochemical failure (A), freedom
from metastasis (B), and prostate cancer-specific mortality
(C) for patients stratified by Gleason score and presence of
Gleason pattern 5. Abbreviations: CI, confidence interval;
GP5, Gleason pattern 5 (primary, secondary, or tertiary); GS,
Gleason score; HR, hazard ratio.
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TABLE 2. Univariate Survival Analysis
Biochemical Failure Distant Metastasis
Prostate Cancer-Specific
Survival
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Pre-SRT PSA (continuous), ng/mL 1.1 (1.06-1.13) <.0001 1.1 (1.1-1.2) <.0001 1.1 (1.0-1.2) .01
Pre-SRT PSADT (continuous), mo 0.96 (0.94-0.98) .0002 0.95 (0.91-0.98) .005 0.88 (0.81-0.96) .002
Any ADT during SRT 0.8 (0.6-1.1) .3 0.9 (0.5-1.4) .6 0.7 (0.5-1.7) .7
Seminal vesicle invasion 2.3 (1.6-3.4) <.0001 2.6 (1.5-4.7) <.0001 3.2 (1.0-6.8) <.0001
Positive margins 0.75 (0.6-1.0) .03 0.8 (0.5-1.2) .3 1.15 (0.7-2.0) .6
Extracapsular extension 1.7 (1.3-2.1) .0001 1.7 (1.1-2.5) .02 2.4 (1.4-4.1) .01
Lymph node involvement 1.5 (0.6-3.6) .3 2.3 (0.5-10.3) .1 3.0 (0.4-21.3) >.05
Abbreviations: ADT, androgen deprivation therapy; CI, confidence interval; GP5, Gleason pattern 5; HR, hazard ratio; PSA, prostate-specific antigen; PSADT,
prostate-specific antigen doubling time; SRT, salvage radiation therapy.
TABLE 3. Competing Risks Multivariate Survival Analysis Including All Variables of Interest
Variable
Biochemical Failure Metastasis
Prostate Cancer-Specific
Mortality
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Gleason Score
2-6 Reference Reference Reference
7 2.1 (1.4-3.1) <.0001 6.4 (2.0-20.0) .001 3.7 (1.2-11.0) .02
8 (414) 2.0 (1.2-3.2) .004 6.0 (1.7-20.9) .01 3.0 (0.9-10.4) .08
GP5 2.9 (1.7-4.7) <.0001 14.4 (4.3-48.8) <.0001 10.8 (3.1-37.9) <.0001
Seminal vesicle invasion 1.6 (1.2-2.2) .002 1.8 (1.1-3.0) .01 2.0 (1.1-3.6) .03
Extracapsular extension 1.5 (1.1-2.0) .01 1.4 (0.9-2.3) .2 1.3 (0.6-2.6) .5
Positive margins 0.5 (0.4-0.7) <.0001 0.6 (0.4-0.9) .04 0.8 (0.4-1.4) .4
Pre-SRT PSA (continuous) 1.1 (1.1-1.2) <.0001 1.2 (1.1-1.3) <.0001 1.2 (1.1-1.2) <.0001
ADT with SRT duration 0.9 (0.9-0.9) <.0001 0.9 (0.9-0.9) <.0001 0.9 (0.9-1.0) .2
Pelvic SRT 0.7 (0.5-1.1) .1 1.1 (0.6-2.1) .8 1.5 (0.7-3.2) .3
SRT start date 0.99 (0.99-1.0) .01 0.99 (0.99-1.0) .2 0.99 (0.99-0.99) <.0001
Abbreviations: ADT, androgen deprivation therapy; CI, confidence interval; GP5, Gleason pattern 5; HR, hazard ratio; PSA, prostate-specific antigen; SRT, sal-
vage radiation therapy.
TABLE 4. Stepwise Competing Risks Multivariate Survival Analysis
Variable
Biochemical Failure Metastasis
Prostate Cancer-Specific
Mortality
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Gleason Score
2-6 Reference Reference Reference
7 2.1 (1.4-3.1) <.0001 6.7 (2.1-22.0) .002 2.2 (1.0-4.5) .04
8 (414) 2.0 (1.2-3.2) .004 6.3 (1.7-22.7) .01 - -
GP5 2.9 (1.8-4.8) <.0001 14.8 (4.2-52.1) <.0001 5.7 (2.3-14.3) <.0001
Seminal vesicle invasion 1.6 (1.1-2.1) .01 2.1 (1.3-3.3) .002 2.3 (1.3-4.3) .01
Extracapsular extension 1.4 (1.1-1.9) .02 - - - -
Positive margins 0.5 (0.4-0.7) <.0001 - - - -
Pre-SRT PSA (continuous) 1.1 (1.1-1.2) <.0001 1.2 (1.1-1.3) <.0001 1.1 (1.1-1.2) <.0001
ADT with SRT duration 0.9 (0.9-0.9) <.0001 0.9 (0.9-0.9) <.0001 - -
Pelvic SRT - - - - - -
SRT start date 0.99 (0.99-0.99) .004 - - 0.99 (0.99-0.99) <.0001
Abbreviations: ADT, androgen deprivation therapy; CI, confidence interval; GP5, Gleason pattern 5; HR, hazard ratio; PSA, prostate-specific antigen; SRT, sal-
vage radiation therapy.
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therapy with either radiation or surgery, GS7 patients
with tertiary GP5 had a similar risk of BF when compared
with patients who had GS9-10, and that this risk was
higher than the risk among patients with GP8 without
GP5.13 Sabolch et al11 evaluated GP5 in patients treated
with dose-escalated EBRT and demonstrated that the
presence of GP was associated with increased DM,
PCSM, and overall mortality compared to GS8 patients
without GP5.
In this study, among men who underwent SRT fol-
lowing RP for localized prostate cancer, we demonstrated
for the first time that the presence of GP5 (primary, sec-
ondary, or tertiary pattern) was the most adverse patho-
logic factor associated with increased BF, DM, and
PCSM on univariate analysis. The increased hazard of
GP5 can be most simply seen in PCSM (Fig. 1C). There
was no difference in PCSM on univariate analysis for any
patient with GS2 to GS8(414) (P> .05) with a 10-year
PCSM rate of 7.7% (SEM 1.5). PCSM was substantially
worse in patients with GP5 than in those with GS8(414)
(HR 2.6, 95% CI 1.1-6.2, P5 .03) with a 10-year PCSM
rate of 30.4% (SEM 7.2). Similar although less profound
results were observed for metastasis (HR 2.2, 95% CI 1.2-
4.2, P5 .02) and BF (HR 1.5, 95% CI 1.0-2.5, P5 .07)
where in each case patients with GP5 had worse metasta-
sis, and BF than those with GS8(414) while there was
substantially less difference in those with GS2 through
GS8(414).
The presence of GP5 was also correlated with other
adverse pathological features, notably pathologic T stage
and the presence of seminal vesicle invasion. However, on
multivariate analysis, the presence of GP5 had the largest
hazard ratio for increased risk of BF, DM, and PCSM.
Additionally, in an exploratory analysis, those with pri-
mary GP5 had worse outcome than those with secondary
or tertiary GP5, suggesting that increasing volumes of
GP5 are associated with an increasing risk of poor clinical
outcome. This finding is consistent with previous reports
suggesting that an increased percentage of Gleason pattern
4 or 5 present on core biopsy or following RP may predict
poorer outcomes.14,20 However, whereas patients with
increasing volumes of GP5 were at greater risk of BF,
DM, and PCSM in our analysis, patients with secondary
or tertiary GP5 were still at a significantly greater risk for
poor outcomes following SRT than patients with
GS8(414) or with lower GS.
It is unclear whether the increased risk of poor clini-
cal outcome associated with GP5 is due to local, regional,
or metastatic failure in patients with GP5. However,
patients with GP5 received SRT sooner than patients
without GP5, were more likely to have BF after SRT, and
had a shorter interval from SRT to BF, where the interval
to BF has been demonstrated to be prognostic for metasta-
sis after RP, EBRT, brachytherapy, and SRT.21-24 As fur-
ther evidence of the increased risk associated with GP5 on
multivariate analysis, those with GP5 were much more
likely to develop metastasis and experience prostate
cancer-specific death than patients with GS8(414), de-
spite the fact that both groups had similar 5-year rates of
BF (74% vs 67%, respectively). Even controlling for the
use of ADT either with SRT or following SRT, where
those with GP5 were more likely to receive either adjuvant
TABLE 5. Stepwise Competing Risks Multivariate Survival Analysis Including Prostate-Specific Antigen Dou-
bling Time
Biochemical Failure Metastasis
Prostate Cancer-Specific
Mortality
Variable p-value HR 95%CI p-value HR 95%CI p-value HR 95%CI
Gleason Score
2-6 Reference Reference Reference
7 0.04 1.5 1.0-2.1 - - - - - -
8 (414) - - - - - - - - -
GP5 0.002 2.3 1.4-3.8 <0.0001 3.0 1.7-5.2 0.02 3.4 1.4-8.4
SVI 0.02 1.7 1.1-2.9 0.004 2.4 1.3-4.3 0.04 2.4 1.0-5.8
ECE 0.01 1.6 1.1-2.4 - - - - - -
Positive Margins <0.0001 0.5 0.4-0.7 - - - - - -
Pre-RT PSA (continuous) <0.0001 1.3 1.2-1.4 <0.0001 1.3 1.2-1.5 <0.0001 1.2 1.2-1.3
Pre-SRT PSADT 0.01 0.9 0.9-0.9 - - - - - -
ADT w/SRT duration 0.001 0.9 0.9-0.9 0.002 0.9 0.8-0.9 - - -
Pelvic SRT - - - - - - - - -
SRT start date - - - - - - 0.01 0.99 0.99-0.99
Abbreviations: ADT, androgen deprivation therapy; CI, confidence interval; GP5, Gleason pattern 5; HR, hazard ratio; PSA, prostate-specific antigen; SRT, sal-
vage radiation therapy.
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or salvage ADT, those with GP5 still progressed to DM
earlier, which would be consistent with GP5 resulting in
higher metastatic potential and also potentially with GP5
being associated with early conversion to androgen
independence.25
Pathologically, GP5 is defined as prostate adenocar-
cinoma with essentially no glandular differentiation, com-
posed of solid sheets, cords, or single cells;
comedocarcinoma with central necrosis surrounded by
papillary cribiform or solid masses,26 thus signifying an
undifferentiated state. This undifferentiated state may
represent one that has lost biological regulation of the
androgen pathway, which could explain our findings
regarding sADT, as well as potentially the aggressive phe-
notype. With the advent of increased understanding of
the biological changes that drive prostate cancer, future
research should aim to define the differences in molecular
pathways driving GP5 disease versus non-GP5 disease.
The ability to highlight the underlying genetic changes
that drive the formation of GP5 disease through advances
in genomics and transcriptome analysis may allow for cre-
ation of targeted therapies that improve outcomes for
patients with GP5 prostate cancer.
Given the poorer prognosis associated with the
presence GP5 in this study, treatment intensification
may be a reasonable option for patients undergoing RP
who are found to harbor GP5. The fact that the presence
of GP5 was independently predictive of DM and PCSM
suggests a need for earlier treatment to prevent seeding of
metastasis, or if earlier treatment is not provided, the
addition of systemic therapy to SRT to account for the
increased risk that micrometastasis may already exist.16
However, it must be noted that the presence of GP5 does
not serve as an absolute contraindication to SRT.
Whereas patients with GP5 have a higher likelihood of
not responding to SRT than those without GP5, those
with localized GP5 recurrences constitute the group of
patients for whom SRT may have the potential to pro-
vide the greatest benefit. This notion that aggressive pros-
tate cancer recurrences benefit most from SRT is
supported by analyses performed by Cotter et al3 and
Trock et al,6 where in both cases SRT was associated
with improved survival in patients with BF after RP com-
pared with observation and the benefit of SRT was great-
est in those with the highest-risk disease. In fact, in our
present analysis, approximately 40% of patients with
GP5 had not developed metastasis 10 years following
SRT, and greater than 65% of patients were still alive.
The major limitations of the present analysis include
the retrospective nature, which necessitates external valida-
tion of these findings, and the long period over which the
cohort received treatment. The Gleason scoring system has
undergone various changes since its inception, most
recently with the changes recommended by the 2005 Inter-
national Society of Urological Pathology consensus confer-
ence.26 However, the majority of changes over the past
decade have revolved around GP4, whereas the definition
of GP5 has remained relatively stable. We attempted to
control for potential changes in the Gleason scoring system
as well as changes in treatment approaches that may have
occurred over the study period by including the start date
of SRT in the multivariate analysis. The start date of SRT
was significantly associated with PCSM, although the HR
(0.99) of approximately 1 resulted in a minor protective
association with more recent SRT start dates, which had
minimal impact upon the overall analysis.
Figure 2. (A) Time to initiation of salvage androgen depriva-
tion therapy after biochemical failure. (B) Time from initiation
of salvage androgen deprivation therapy to the development
of metastasis. Abbreviations: ADT, androgen deprivation ther-
apy; CI, confidence interval; HR, hazard ratio.
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In conclusion, we for the first time demonstrate
that the presence of GP5 is critically associated with clin-
ically significant outcomes in the setting of SRT follow-
ing RP. GP5 was the most adverse pathologic risk factor
on univariate and multivariate analysis, despite the earlier
and more prevalent use of sADT in these patients. Addi-
tionally, restratification of the Gleason scoring system
with the presence of GP5 defining the highest-risk group
was a better predictor of patient outcomes than the tradi-
tional Gleason scoring system. Clearly, patients with
GP5 do not have the same clinical prognosis as patients
with GS8(414), and thus the two should not be consid-
ered as one entity when stratifying patient risk by Glea-
son score.7,17 Future risk stratification schemes and
predictive nomograms for SRT candidates following RP
for prostate cancer should account for the presence of
GP5, as the results here suggest that this one factor could
have a greater influence on prognostic tools than any
other variable. Intensification of treatment regimens,
with initiation of adjuvant therapy following RP or the
concurrent use of systemic therapies at the time of SRT
may be reasonable options for patients with GP5 follow-
ing radical prostatectomy.
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